147 related articles for article (PubMed ID: 19961222)
61. Synthesis and biological activity of potent HIV-1 protease inhibitors based on Phe-Pro dihydroxyethylene isosteres.
Benedetti F; Berti F; Budal S; Campaner P; Dinon F; Tossi A; Argirova R; Genova P; Atanassov V; Hinkov A
J Med Chem; 2012 Apr; 55(8):3900-10. PubMed ID: 22458611
[TBL] [Abstract][Full Text] [Related]
62. Synthesis of novel, potent, diol-based HIV-1 protease inhibitors via intermolecular pinacol homocoupling of (2S)-2-benzyloxymethyl-4-phenylbutanal.
Mühlman A; Lindberg J; Classon B; Unge T; Hallberg A; Samuelsson B
J Med Chem; 2001 Oct; 44(21):3407-16. PubMed ID: 11585446
[TBL] [Abstract][Full Text] [Related]
63. Synthesis, 2D-NMR and molecular modelling studies of pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA protease inhibitors.
Makatini MM; Petzold K; Alves CN; Arvidsson PI; Honarparvar B; Govender P; Govender T; Kruger HG; Sayed Y; JerônimoLameira ; Maguire GE; Soliman ME
J Enzyme Inhib Med Chem; 2013 Feb; 28(1):78-88. PubMed ID: 22339087
[TBL] [Abstract][Full Text] [Related]
64. Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors.
Wu X; Ohrngren P; Joshi AA; Trejos A; Persson M; Arvela RK; Wallberg H; Vrang L; Rosenquist A; Samuelsson BB; Unge J; Larhed M
J Med Chem; 2012 Mar; 55(6):2724-36. PubMed ID: 22376008
[TBL] [Abstract][Full Text] [Related]
65. Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue.
Mak CC; Le VD; Lin YC; Elder JH; Wong CH
Bioorg Med Chem Lett; 2001 Jan; 11(2):219-22. PubMed ID: 11206463
[TBL] [Abstract][Full Text] [Related]
66. Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR.
Barrish JC; Gordon E; Alam M; Lin PF; Bisacchi GS; Chen P; Cheng PT; Fritz AW; Greytok JA; Hermsmeier MA
J Med Chem; 1994 Jun; 37(12):1758-68. PubMed ID: 8021916
[TBL] [Abstract][Full Text] [Related]
67. Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere.
Hidaka K; Kimura T; Hayashi Y; McDaniel KF; Dekhtyar T; Colletti L; Kiso Y
Bioorg Med Chem Lett; 2003 Jan; 13(1):93-6. PubMed ID: 12467624
[TBL] [Abstract][Full Text] [Related]
68. Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.
Mühlman A; Classon B; Hallberg A; Samuelsson B
J Med Chem; 2001 Oct; 44(21):3402-6. PubMed ID: 11585445
[TBL] [Abstract][Full Text] [Related]
69. HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues.
Lockbaum GJ; Rusere LN; Henes M; Kosovrasti K; Rao DN; Spielvogel E; Lee SK; Nalivaika EA; Swanstrom R; Yilmaz NK; Schiffer CA; Ali A
Eur J Med Chem; 2023 Sep; 257():115501. PubMed ID: 37244161
[TBL] [Abstract][Full Text] [Related]
70. Inhibitors of the protease from human immunodeficiency virus: synthesis, enzyme inhibition, and antiviral activity of a series of compounds containing the dihydroxyethylene transition-state isostere.
Thaisrivongs S; Turner SR; Strohbach JW; TenBrink RE; Tarpley WG; McQuade TJ; Heinrikson RL; Tomasselli AG; Hui JO; Howe WJ
J Med Chem; 1993 Apr; 36(8):941-52. PubMed ID: 8478908
[TBL] [Abstract][Full Text] [Related]
71. Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors containing a stereochemically unique peptide isostere.
Holmes DS; Bethell RC; Cammack N; Clemens IR; Kitchin J; McMeekin P; Mo CL; Orr DC; Patel B; Paternoster IL
J Med Chem; 1993 Oct; 36(21):3129-36. PubMed ID: 8230099
[TBL] [Abstract][Full Text] [Related]
72. 5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.
Boyer FE; Vara Prasad JV; Domagala JM; Ellsworth EL; Gajda C; Hagen SE; Markoski LJ; Tait BD; Lunney EA; Palovsky A; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Sanders JM; VanderRoest S; Brodfuehrer J; Iyer K; Sinz M; Gulnik SV
J Med Chem; 2000 Mar; 43(5):843-58. PubMed ID: 10715152
[TBL] [Abstract][Full Text] [Related]
73. HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity.
Young SD; Payne LS; Thompson WJ; Gaffin N; Lyle TA; Britcher SF; Graham SL; Schultz TH; Deana AA; Darke PL
J Med Chem; 1992 May; 35(10):1702-9. PubMed ID: 1588552
[TBL] [Abstract][Full Text] [Related]
74. Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors.
Romines KR; Watenpaugh KD; Tomich PK; Howe WJ; Morris JK; Lovasz KD; Mulichak AM; Finzel BC; Lynn JC; Horng MM
J Med Chem; 1995 May; 38(11):1884-91. PubMed ID: 7783120
[TBL] [Abstract][Full Text] [Related]
75. Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
Dorsey BD; McDonough C; McDaniel SL; Levin RB; Newton CL; Hoffman JM; Darke PL; Zugay-Murphy JA; Emini EA; Schleif WA; Olsen DB; Stahlhut MW; Rutkowski CA; Kuo LC; Lin JH; Chen IW; Michelson SR; Holloway MK; Huff JR; Vacca JP
J Med Chem; 2000 Sep; 43(18):3386-99. PubMed ID: 10978186
[TBL] [Abstract][Full Text] [Related]
76. Facile syntheses of C2-symmetrical HIV-1 protease inhibitors.
König S; Ugi I; Schramm HJ
Arch Pharm (Weinheim); 1995 Oct; 328(10):699-704. PubMed ID: 8554458
[TBL] [Abstract][Full Text] [Related]
77. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
Hagen SE; Domagala J; Gajda C; Lovdahl M; Tait BD; Wise E; Holler T; Hupe D; Nouhan C; Urumov A; Zeikus G; Zeikus E; Lunney EA; Pavlovsky A; Gracheck SJ; Saunders J; VanderRoest S; Brodfuehrer J
J Med Chem; 2001 Jul; 44(14):2319-32. PubMed ID: 11428926
[TBL] [Abstract][Full Text] [Related]
78. A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.
Tucker TJ; Lumma WC; Payne LS; Wai JM; de Solms SJ; Giuliani EA; Darke PL; Heimbach JC; Zugay JA; Schleif WA
J Med Chem; 1992 Jul; 35(14):2525-33. PubMed ID: 1635054
[TBL] [Abstract][Full Text] [Related]
79. Synthesis of potent and orally active HIV-protease inhibitors.
Capraro HG; Bold G; Fässler A; Cozens R; Klimkait T; Lazdins J; Mestan J; Poncioni B; Rösel JL; Stover D; Lang M
Arch Pharm (Weinheim); 1996 Jun; 329(6):273-8. PubMed ID: 8767110
[TBL] [Abstract][Full Text] [Related]
80. Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.
Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; Rosenbrook W; Herrin T; Li L; Madigan D; Vasavanonda S; Molla A; Saldivar A; McDonald E; Wideburg NE; Kempf D; Norbeck DW; Plattner JJ
Biochem Biophys Res Commun; 1996 Aug; 225(2):436-40. PubMed ID: 8753780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
